ScribeAmerica

Belkins
"The Standard in Professional Scribe Training and Management" ScribeAmerica's mission is to assist the physician by training scribes in how to intelligently share the provider's burden of data gathering and EMR documentation. In doing so, the physician's individual productivity and patient throughput increase, so that the goal of providing cost effective, quality medical care is achieved.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TRUMP TRADE ADVISER, CITING 'BROKEN SYSTEM,' CALLS FOR MORE DRUG MANUFACTURING IN PUERTO RICO

Fiercepharma | June 01, 2020

news image

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. The COVID-19 pandemic has underscored key weaknesses in the biopharma industry’s complex global supply chain, and now a top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico. In an interview with the Washington Examiner, White House trade advis...

Read More

BUSINESS INSIGHTS

ORSINI SPECIALTY PHARMACY SELECTED BY SANOFI AS A LIMITED DISTRIBUTION PARTNER FOR NEXVIAZYME®

Orsini Specialty Pharmacy | September 28, 2021

news image

Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that Sanofi has selected it as a limited distribution partner for Nexviazyme® (avalglucosidase alfa-ngpt). Nexviazyme, an enzyme replacement therapy (ERT), is used for treating patients one year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). This progressive and debilitating muscle disorder impairs a person's abi...

Read More

INTEC PHARMA ANNOUNCES NEW RESEARCH COLLABORATION AGREEMENT WITH MSD

Intec Pharma | October 08, 2020

news image

Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows t...

Read More

BEIGENE REPORTS POSITIVE PHASE III INTERIM ANALYSIS FOR LUNG CANCER DRUG

MedCity News | April 14, 2020

news image

Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without their disease worsening, the company developing the drug said Monday. Beijing-based BeiGene reported an improvement in progression-free survival (PFS) among first-line patients with non-squamous non-small-cell lung cancer (NSCLC) receiving tislelizumab along with ...

Read More

Fiercepharma | June 01, 2020

news image

TRUMP TRADE ADVISER, CITING 'BROKEN SYSTEM,' CALLS FOR MORE DRUG MANUFACTURING IN PUERTO RICO

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. The COVID-19 pandemic has underscored key weaknesses in the biopharma industry’s complex global supply chain, and now a top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico. In an interview with the Washington Examiner, White House trade advis...

Read More

BUSINESS INSIGHTS

Orsini Specialty Pharmacy | September 28, 2021

news image

ORSINI SPECIALTY PHARMACY SELECTED BY SANOFI AS A LIMITED DISTRIBUTION PARTNER FOR NEXVIAZYME®

Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that Sanofi has selected it as a limited distribution partner for Nexviazyme® (avalglucosidase alfa-ngpt). Nexviazyme, an enzyme replacement therapy (ERT), is used for treating patients one year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). This progressive and debilitating muscle disorder impairs a person's abi...

Read More

Intec Pharma | October 08, 2020

news image

INTEC PHARMA ANNOUNCES NEW RESEARCH COLLABORATION AGREEMENT WITH MSD

Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows t...

Read More

MedCity News | April 14, 2020

news image

BEIGENE REPORTS POSITIVE PHASE III INTERIM ANALYSIS FOR LUNG CANCER DRUG

Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without their disease worsening, the company developing the drug said Monday. Beijing-based BeiGene reported an improvement in progression-free survival (PFS) among first-line patients with non-squamous non-small-cell lung cancer (NSCLC) receiving tislelizumab along with ...

Read More